Monday May 8th
08.00-09.00 Coffee and Registration
09.00-09.20
Remembering Jouni Uitto
John McGrath (UK)
09.20-09.55
Current best practice clinical care for EB
Jemima Mellerio (UK)
09.55-10.20
Measuring clinical activity/severity of EB in clinic and in clinical trials
Dedee Murrell (Australia)
10.20 – 10.40 Coffee/Tea Break
10.40-11.00
EB therapeutics: lessons from stem cell biology and transplantation
Jakub Tolar (USA)
11.00 -11.20
Progress in cell therapies for EB
Dimitra Kiritsi (Germany)
11.20-11.40
Understanding cancer in EB
Veli-Matti Kahari (Finland)
11.40-12.00
Cancer therapeutics in EB
Andrew South (USA)
12.00-13.00 Lunch
13.00-13.20
Gene therapy for RDEB: my experience
Su Lwin (UK)
13.20-13.40
Gene therapy for RDEB: my experience
Alain Hovnanian (France)
13.40-14.00
Gene therapy for RDEB: my experience
Peter Marinkovich (USA)
14.00-14.20
Improving gene function in EB
David Woodley (USA)
14.20-14.40
Developing gene editing for EB
Joanna Jackow (UK)
14.40-15.00 Coffee/Tea break
15.00-15.20
Innovative treatments for EB simplex
Johann Bauer (Austria)
15.20-15.40
Biologics in the management of EB
Chao-Kai Hsu (Taiwan)
15.40-16.00
Innovative treatments for EB
Francis Palisson (Chile)
16.00-17.00
Jouni Uitto International Lectureship Award
Katsuto Tamai (Japan)
(Hosted by Andrew South on behalf of Jefferson Medical College)
17.00 Close for day
18.45-20.30
Conference dinner (Senri-Hankyu Hotel)
Tuesday May 9th
08.00-08.30 Coffee and Registration
EB research and patient care in Japan
08.30-08.45
Introduction of Debra Japan
Keiko Miyamoto (Sapporo/Japan)/Akira Ishiko (Tokyo/Japan)
08.45-09.00
Japanese government support system of EB treatment/care
Satoru Shinkuma (Nara/Japan)
09.00-09.15
Evaluation of revertant mosaicism in EB
Ken Natsuga (Sapporo/Japan)
09.15-09.30
Transplantation of revertant epithelia to RDEB skin
Akiharu Kubo (Kobe/Japan)
EB therapeutics: perspectives from Pharma/Industry
09.30-09.50
J-TEC
09.50-10.05
Convatec
10.05-10.20
Mölnlycke s
10.20-10.40 Coffee/Tea Break
10.40-11.00
StemRIM
11.00-11.30
Amryt Pharma
11.30-12.00
Krystal Biotech
12.00-13.00 Lunch
13.00-13.30
Onconova Therapeutics
13.30-13.45
TWi Biotechnology
13.45-14.00
RHEACELL
Recommendations and action plans for treating EB
14.00-15.00
Group and multi-stakeholder consensus session
Moderator: John McGrath